SCR tests low-cost anti-collision system

SCR tests low-cost anti-collision system
x
Highlights

SCR tests low-cost anti-collision system. The trials of Train Collision Avoidance System (TCAS) system, also called as Automatic Train Protection (ATP) System, an indigenous ‘Make in India’ project of Indian Railways, was carried our between Lingampalli-Vikarabad-Tandur and Koukuntla railway stations on the Begumpet - Wadi Section.

The trials of Train Collision Avoidance System (TCAS) system, also called as Automatic Train Protection (ATP) System, an indigenous ‘Make in India’ project of Indian Railways, was carried our between Lingampalli-Vikarabad-Tandur and Koukuntla railway stations on the Begumpet - Wadi Section.

Naveen Tandon, member, electrical, Railway Board, New Delhi, examined the trials. The TCAS, developed indigenously by Research Designs & Standards Organisation (RDSO), Lucknow, is being extended infrastructural support by South Central Railway.

The Automatic Train Protection System, which is economical as compared to the technology in developed countries, was put on trial, as a continuing measure to the trials carried out earlier in the same section.

The TCAS trials were broadly categorised into three segments - between Godamgura and Tandur, it was a maiden trial of the new installation of TCAS while between Tandur and Koukuntla, the trials were meant to further ensure inter operability with three firms viz., Medha, Kernex and HBL which are involved in the project.

Between Lingampalli and Hafizpet, the maiden trials were carried out to check suitability of TCAS on auto signaling section. The ambitious project is being further planned for full fledged extended trials in the next few months by undertaking work on required infrastructural inputs including tower foundations, equipment installations etc.

The full fledged trials will cover Lingampalli – Vikarabad – Wadi and Vikarabad – Bidar sections upto a total length of 250 km. 40 nominated locomotives (20 electrical and 20 diesel locomotives) will be put to use for these full-fledged trials.

Show Full Article
Print Article
Next Story
More Stories
ADVERTISEMENT
ADVERTISEMENTS